Literature DB >> 7150475

Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.

P Workman, P R Twentyman.   

Abstract

Using a regrowth-delay assay, we investigated structure/activity relationships for the enhancement by electron-affinic agents of the anti-tumour effect of the nitrosourea CCNU against the KHT sarcoma in C3H mice. A series of neutral 2-nitroimidazoles similar in electron affinity but varying in octanol/water partition coefficient (PC) over 4 orders of magnitude (0.016- greater than 200, Misonidazole = 0.43) were examined at a fixed dose of 2.5 mmol/kg. A parabolic (quadratic) dependence of activity on log PC was observed. Analogues more hydrophilic than misonidazole (MISO) were inactive as were those with very high PCs (greater than 20). Those with PC 0.43--20 were usually more active than MISO, some considerably so. The fairly lipophilic 5-nitroimidazoles nimorazole and metronidazole (METRO) had similar activity to MISO, despite their reduced electron affinity. Two basic 2-nitroimidazoles more efficient as radiosensitizers in vitro likewise showed activity comparable to MISO. We also investigated several agents more electron-affinic than MISO, including some non-nitro compounds. Most were inactive at maximum tolerated doses, but nitrofurazone showed reasonable activity. Sensitizer dose-response curves were obtained for MISO, METRO and two of the most effective agents, benznidazole (Ro 07-1051) and Ro 07-1902. The two latter agents were both considerably more active than MISO at low doses (0.1--0.9 mmol/kg). These studies indicate that the structural features of electron-affinic agents responsible for the enhancement of KHT tumour response to CCNU, are quite different from those affecting radiosensitization, lipophilicity being particularly important. The microsomal enzyme-inhibitor SKF 525A increased the anti-tumour effect of CCNU, suggesting inhibition of CCNU metabolism as one possible mechanism contributing to chemosensitization by lipophilic electron-affinic agents in mice.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7150475      PMCID: PMC2011106          DOI: 10.1038/bjc.1982.190

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Alterations in the toxicity and antitumor activity of methyl-CCNU in mice following pretreatment with either phenobarbital or SKF 525A.

Authors:  P Klubes; H G Miller; I Cerna; J Trevithick
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

2.  The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin.

Authors:  P R Twentyman; R F Kallman; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-08       Impact factor: 7.038

3.  Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole.

Authors:  J M Brown; P Workman
Journal:  Radiat Res       Date:  1980-04       Impact factor: 2.841

4.  Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors.

Authors:  R F Kallman; G Silini; L M Van Putten
Journal:  J Natl Cancer Inst       Date:  1967-09       Impact factor: 13.506

5.  Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency.

Authors:  G E Adams; E D Clarke; I R Flockhart; R S Jacobs; D S Sehmi; I J Stratford; P Wardman; M E Watts; J Parrick; R G Wallace; C E Smithen
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1979-02

6.  Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential.

Authors:  G E Adams; I J Stratford; R G Wallace; P Wardman; M E Watts
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

7.  Structure-activity relationships in the development of hypoxic cell radiosensitizers. III. Effects of basic substituents in nitroimidazole sidechains.

Authors:  G E Adams; I Ahmed; E D Clarke; P O'Neill; J Parrick; I J Stratford; R G Wallace; P Wardman; M E Watts
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1980-12

8.  Response of the solid Guerin epitheliomas of rats to fractionated irradiation and a new 4-nitroimidazole.

Authors:  J Watras; M Wideł; J Suwiński
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640

9.  In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.

Authors:  I F Tannock
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640

10.  In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.

Authors:  R T Mulcahy; D W Siemann; R M Sutherland
Journal:  Br J Cancer       Date:  1981-01       Impact factor: 7.640

View more
  11 in total

1.  Clinical pharmacokinetics of oral CCNU (lomustine).

Authors:  F Y Lee; P Workman; J T Roberts; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Treatment of malignant gliomas in adults with BCNU plus metronidazole.

Authors:  D J Stewart; B Benoit; M T Richard; H Hugenholtz; J Dennery; N Russell; E Peterson; Z Grahovac; G Belanger; J A Maroun
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

3.  Mitomycin-C plus metronidazole in advanced carcinoma of the breast.

Authors:  D J Stewart; J A Maroun; B Lefebvre; R Heringer; A F Crook
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.

Authors:  K H Wong; C A Wallen; K T Wheeler
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

5.  Twenty-fifth annual general meeting of the British Association for Cancer Research. Abstracts of invited and profferred papers.

Authors: 
Journal:  Br J Cancer       Date:  1984-08       Impact factor: 7.640

6.  Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.

Authors:  D G Hirst; J L Hazlehurst; J M Brown
Journal:  Br J Cancer       Date:  1984-01       Impact factor: 7.640

7.  Preclinical pharmacokinetics of benznidazole.

Authors:  P Workman; R A White; M I Walton; L N Owen; P R Twentyman
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

8.  Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

9.  The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.

Authors:  M Hinchliffe; N J McNally; M R Stratford
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

10.  Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.